Arvinas (NASDAQ:ARVN) Posts Earnings Results, Misses Estimates By $0.55 EPS

Arvinas (NASDAQ:ARVN) posted its quarterly earnings data on Tuesday. The company reported ($1.10) earnings per share for the quarter, missing the consensus estimate of ($0.55) by ($0.55), Briefing.com reports. Arvinas had a negative net margin of 18.73% and a negative return on equity of 9.77%. The company had revenue of $9.50 million for the quarter, compared to analysts’ expectations of $37.26 million. During the same quarter last year, the business posted ($0.63) EPS. The business’s quarterly revenue was down 84.0% compared to the same quarter last year.

Here are the key takeaways from Arvinas’ conference call:

• Arvinas expects multiple data readouts in 2026 from its clinical PROTACs (ARV-102, ARV-806, ARV-393, ARV-027) and plans a first-in-human for ARV-6723, positioning the company for several near-term value-driving milestones.
• ARV-102 demonstrated >50% LRRK2 reduction in CSF with pathway biomarker engagement (GPNMB, CD68), was accepted for an oral presentation at ADPD, and Arvinas plans a Phase 1b in PSP with a potential registrational trial in late 2026 pending regulatory feedback.
• The KRAS G12D degrader ARV-806 enrolled faster than expected with initial clinical data anticipated by mid-2026 (company cites strong preclinical potency and durable degradation), and the BCL6 degrader ARV-393 has already shown responses in early lymphoma cohorts and is advancing toward combination studies with glofitamab.
• Financially, Arvinas ended Q4 with ~$685M in cash (down from >$1B), maintains guidance for cash into the second half of 2028 after cost cuts, and has suspended its $100M repurchase program after buying back ~$91.9M.
• For vepdegestrant, Arvinas and Pfizer are actively selecting a commercialization partner ahead of the June 5 PDUFA to ensure launch readiness if approved, but a deal is not yet finalized.

Arvinas Price Performance

ARVN opened at $12.37 on Wednesday. The stock’s 50 day simple moving average is $12.37 and its 200 day simple moving average is $10.51. The firm has a market cap of $794.40 million, a price-to-earnings ratio of -15.27 and a beta of 1.88. Arvinas has a 1 year low of $5.90 and a 1 year high of $18.93.

Insider Buying and Selling at Arvinas

In other news, CFO Andrew Saik sold 5,134 shares of the stock in a transaction that occurred on Friday, February 13th. The stock was sold at an average price of $11.89, for a total transaction of $61,043.26. Following the completion of the sale, the chief financial officer owned 159,267 shares of the company’s stock, valued at approximately $1,893,684.63. This represents a 3.12% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Noah Berkowitz sold 5,685 shares of Arvinas stock in a transaction on Friday, February 13th. The stock was sold at an average price of $11.89, for a total transaction of $67,594.65. Following the completion of the transaction, the insider directly owned 163,938 shares in the company, valued at approximately $1,949,222.82. The trade was a 3.35% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 16,238 shares of company stock worth $193,070. 4.73% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Arvinas

A number of hedge funds have recently modified their holdings of ARVN. AQR Capital Management LLC purchased a new stake in shares of Arvinas during the first quarter worth about $727,000. Jacobs Levy Equity Management Inc. bought a new position in Arvinas during the 1st quarter valued at approximately $301,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in Arvinas by 5.8% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 38,636 shares of the company’s stock worth $271,000 after buying an additional 2,122 shares during the period. Millennium Management LLC lifted its holdings in Arvinas by 208.4% in the 1st quarter. Millennium Management LLC now owns 1,310,326 shares of the company’s stock worth $9,198,000 after buying an additional 885,483 shares during the period. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in shares of Arvinas by 108.3% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 902,925 shares of the company’s stock worth $6,339,000 after buying an additional 469,394 shares during the last quarter. Hedge funds and other institutional investors own 95.19% of the company’s stock.

More Arvinas News

Here are the key news stories impacting Arvinas this week:

• Positive Sentiment: Company says it has a cash runway into the second half of 2028 and outlined multiple 2026 clinical-data milestones (ARV-102, ARV-806, ARV-393) that could drive value if readouts are positive. This financial runway reduces near-term financing risk and supports ongoing development. Arvinas outlines 2026 clinical data milestones and maintains cash runway into second half of
• Positive Sentiment: Program progress: ARV-102 (LRRK2) accepted for an oral presentation at AP/PD; ARV-806 (KRAS G12D) and ARV-393 (BCL6) clinical data on track; ARV-027 Phase 1 in healthy volunteers started; ARV-6723 Phase 1 planned mid-2026. Management change (Randy Teel, Ph.D., named CEO) also highlighted. These operational updates support a constructive view on pipeline execution. Arvinas Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
• Neutral Sentiment: Management is increasing investor access (TD Cowen fireside chat and other conferences in early March), which could improve visibility and catalyze re-assessment of the pipeline by sell-side and institutional investors. Arvinas to Participate in Upcoming Investor Conferences
• Neutral Sentiment: Intraday volume was noticeably higher than average and the stock is trading above its 50-day moving average, suggesting short-term investor interest and technical buying even amid mixed fundamentals. (Market trading data)
• Negative Sentiment: Q4 2025 results materially missed expectations: GAAP EPS of -$1.10 vs. consensus -$0.55 and revenue $9.5M vs. $37.3M expected (revenue down ~84% YoY). The magnitude of the revenue shortfall and larger-than-expected loss raise near-term execution and commercial concerns. Arvinas, Inc. (ARVN) Reports Q4 Loss, Misses Revenue Estimates
• Negative Sentiment: Analyst outlook remains negative on near-term profitability (consensus and analyst commentary point to continuing losses and negative EPS for the year), which limits upside until clinical readouts materially de-risk programs. 4ARVN : Arvinas’s Earnings Outlook

Wall Street Analyst Weigh In

A number of research analysts recently commented on the company. Wall Street Zen raised Arvinas from a “sell” rating to a “hold” rating in a research note on Sunday. BTIG Research upped their price objective on Arvinas from $10.00 to $14.00 and gave the stock a “buy” rating in a report on Thursday, October 30th. Wells Fargo & Company decreased their price objective on Arvinas from $16.00 to $15.00 and set an “overweight” rating on the stock in a report on Thursday, November 6th. Barclays boosted their target price on Arvinas from $16.00 to $18.00 and gave the stock an “overweight” rating in a research report on Wednesday, December 17th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Arvinas in a research note on Monday, December 22nd. Ten equities research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Hold” and an average target price of $13.24.

About Arvinas

Arvinas, Inc (NASDAQ: ARVN) is a biopharmaceutical company focused on the development of therapies based on targeted protein degradation. Utilizing its proprietary proteolysis-targeting chimera (PROTAC®) platform, Arvinas aims to selectively eliminate disease-causing proteins rather than merely inhibit their activity. This novel approach has the potential to address a range of diseases, including oncology, neurodegeneration and inflammation, by harnessing the body’s natural protein-recycling systems.

The company’s most advanced clinical candidates address hormone-driven cancers.